Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

10.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Neural Regulation01:37

Neural Regulation

39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Inflammatory Potential of Key Phytochemicals From Humboldtia sanjappae: In Vivo Studies and Molecular Docking With MM-GBSA Analysis.

Chemistry & biodiversity·2026
Same author

Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer's Disease.

Molecular pharmaceutics·2025
Same author

Design of Experiments Approach for the Development of a Validated UPLC-Q-ToF/MS Method to Quantitate Soy-Derived Bioactive Peptide Lunasin in Rabbit Plasma: Application to a Pharmacokinetic Study.

Biomedical chromatography : BMC·2025
Same author

Co-targeting of HMG-Co-A Reductase and Cycloxygenase-2 for the Treatment of Non-small Cell Lung Cancer.

Advanced pharmaceutical bulletin·2024
Same author

Translational Challenges in Cancer Nanotherapy.

Advanced pharmaceutical bulletin·2024
Same author

Correction: Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease.

Neurochemical research·2024

Related Experiment Video

Updated: May 15, 2025

Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells
11:47

Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells

Published on: April 3, 2019

8.8K

Purinergic Receptor (P2X7R): A Promising Anti-Parkinson's Drug Target.

Saivarshini Magham1, M Lalith Kumar1, Praveen Thaggikuppe Krishnamurthy1

  • 1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The Nilgiris, Tamil Nadu, India.

Advanced Pharmaceutical Bulletin
|April 7, 2025
PubMed
Summary

Targeting Purinergic 2X7 receptors (P2X7R) with antagonists shows promise for Parkinson's disease (PD) treatment. These antagonists may offer neuroprotection by reducing inflammation, a key factor in PD pathology.

Keywords:
ATPAllosteric antagonistsCNSMicrogliaP2X7RPD

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.3K
Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization
09:49

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization

Published on: May 12, 2017

10.3K

Related Experiment Videos

Last Updated: May 15, 2025

Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells
11:47

Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells

Published on: April 3, 2019

8.8K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.3K
Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization
09:49

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization

Published on: May 12, 2017

10.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Parkinson's disease (PD) is a major neurodegenerative disorder linked to dopamine depletion and neuroinflammation.
  • Purinergic 2X7 receptors (P2X7Rs) act as key regulators of inflammation, particularly in glial cells within the central and peripheral nervous systems.
  • Overexpression of P2X7Rs in glial cells contributes significantly to the neuroinflammation observed in PD.

Purpose of the Study:

  • To review the structure, signaling, and molecular mechanisms of P2X7 receptors.
  • To explore the neuroprotective role of P2X7 receptor antagonists in Parkinson's disease.
  • To summarize current developments in P2X7 receptor antagonist research for PD treatment.

Main Methods:

  • Systematic analysis and review of existing research data and reports.
  • Literature search focused on publications from 1996 to the present.
  • Analysis of studies investigating the link between P2X7R and PD pathology.

Main Results:

  • A strong correlation exists between P2X7 receptor activity and the pathology of Parkinson's disease.
  • P2X7 receptor antagonists demonstrate significant therapeutic potential for treating PD.
  • Evidence suggests P2X7R antagonists can prevent the release of inflammatory mediators like IL-1, offering neuroprotection.

Conclusions:

  • P2X7 receptor is a validated and effective therapeutic target for Parkinson's disease.
  • Advances in drug design have led to the development of promising P2X7 receptor antagonists, including adamantyl cyanoguanides and small molecular compounds.
  • Further research is needed to fully elucidate the molecular mechanisms and therapeutic efficacy of P2X7 receptor antagonists in PD.